T2 Biosystems, Inc. (TTOO) Reaches $8.20 After 5.00% Up Move; 0 Bullish Analysts Covering Dot Hill Systems (HILL)

May 20, 2018 - By Adrian Mccoy

T2 Biosystems, Inc. (NASDAQ:TTOO) Logo

Among 2 analysts covering Dot Hill Systems (NASDAQ:HILL), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Dot Hill Systems had 3 analyst reports since August 19, 2015 according to SRatingsIntel. The stock of Dot Hill Systems Corporation (NASDAQ:HILL) has “Neutral” rating given on Wednesday, August 19 by Sidoti. Piper Jaffray downgraded the shares of HILL in report on Wednesday, August 19 to “Neutral” rating. See Dot Hill Systems Corporation (NASDAQ:HILL) latest ratings:

The stock of T2 Biosystems, Inc. (NASDAQ:TTOO) is a huge mover today! The stock increased 13.89% or $1 during the last trading session, reaching $8.2. About 1.27 million shares traded or 280.49% up from the average. T2 Biosystems, Inc. (NASDAQ:TTOO) has risen 12.64% since May 20, 2017 and is uptrending. It has outperformed by 1.09% the S&P500.The move comes after 8 months positive chart setup for the $295.36M company. It was reported on May, 20 by Barchart.com. We have $8.61 PT which if reached, will make NASDAQ:TTOO worth $14.77 million more.

More notable recent T2 Biosystems, Inc. (NASDAQ:TTOO) news were published by: Globenewswire.com which released: “T2 Biosystems Reports Granting of Inducement Awards” on May 03, 2018, also Seekingalpha.com with their article: “T2 Biosystems’ (TTOO) CEO John McDonough on Q1 2018 Results – Earnings Call Transcript” published on May 14, 2018, Schaeffersresearch.com published: “2 Upgraded Drug Stocks Squeezing Shorts” on May 09, 2018. More interesting news about T2 Biosystems, Inc. (NASDAQ:TTOO) were released by: Nasdaq.com and their article: “T2 Biosystems Reports First Quarter 2018 Financial Results and Provides Corporate Update” published on May 08, 2018 as well as Seekingalpha.com‘s news article titled: “Premarket analyst action – healthcare” with publication date: May 09, 2018.

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. The company has market cap of $295.36 million. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. It currently has negative earnings. The firm also offers T2Dx, a bench-top instrument for sepsis, Lyme disease, and other applications, as well as T2Candida panel for the detection of candida species in human whole blood specimens.

Among 9 analysts covering T2 Biosystems Inc (NASDAQ:TTOO), 6 have Buy rating, 1 Sell and 2 Hold. Therefore 67% are positive. T2 Biosystems Inc had 25 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of T2 Biosystems, Inc. (NASDAQ:TTOO) has “Market Perform” rating given on Thursday, November 10 by Leerink Swann. The stock has “Neutral” rating by Janney Capital on Tuesday, April 12. As per Wednesday, November 2, the company rating was maintained by Cantor Fitzgerald. The firm has “Buy” rating by Canaccord Genuity given on Wednesday, March 7. The rating was upgraded by BTIG Research to “Buy” on Thursday, September 3. H.C. Wainwright maintained it with “Buy” rating and $8.0 target in Monday, February 12 report. BTIG Research initiated the shares of TTOO in report on Tuesday, July 21 with “Neutral” rating. As per Sunday, August 16, the company rating was maintained by BTIG Research. On Tuesday, October 27 the stock rating was initiated by Canaccord Genuity with “Buy”. Canaccord Genuity maintained the stock with “Buy” rating in Monday, October 30 report.

Analysts await T2 Biosystems, Inc. (NASDAQ:TTOO) to report earnings on August, 2. They expect $-0.34 earnings per share, up 32.00% or $0.16 from last year’s $-0.5 per share. After $-0.36 actual earnings per share reported by T2 Biosystems, Inc. for the previous quarter, Wall Street now forecasts -5.56% EPS growth.

It closed at $9.75 lastly. It is down 0.00% since May 20, 2017 and is . It has underperformed by 11.55% the S&P500.

T2 Biosystems, Inc. (NASDAQ:TTOO) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: